OPEN

Citation: Nutrition & Diabetes (2014) 4, e143; doi:10.1038/nutd.2014.40 © 2014 Macmillan Publishers Limited All rights reserved 2044-4052/14 www.nature.com/nutd

MINI REVIEW

Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin B Haas1,3, N Eckstein1,2,3, V Pfeifer1, P Mayer1 and MDS Hass1 Prevalence of diabetes mellitus is inc6reasing, with a burden of 382 million patients worldwide at present (more than the entire US population). The International Diabetes Federation anticipates an increase up to 592 million patients by 2035. Another major problem arises from the fact that just 50% of patients with type 2 diabetes mellitus are at target glycaemic control with currently available medications. Therefore, a clear need for new therapies that aim to optimize glycaemic control becomes evident. Renal sodium-linked glucose transporter 2 inhibitors are new antidiabetic drugs with an insulin-independent mechanism of action. They pose one remarkable advantage compared with already established antidiabetics: increasing urinary glucose excretion without inducing hypoglycaemia, thereby promoting body weight reduction due to loss of ~ 300 kcal per day. This review focuses on canagliflozin, which was the first successful compound of this class to be approved by both the US Food and Drug Administration and the European Medicines Agency in 2013. Clinical trials showed promising results: enhancing glycaemic control was paralleled by reducing body weight and systolic and diastolic blood pressure. Nevertheless, some safety concerns remain, such as genital mycotic infections, urinary tract infections and cardiovascular risks in vulnerable patients, which will be closely monitored in several post-authorization safety studies. Nutrition & Diabetes (2014) 4, e143; doi:10.1038/nutd.2014.40; published online 3 November 2014

INTRODUCTION Typical features of type 2 diabetes mellitus (T2DM) are insulin resistance of various organs such as liver, muscle and adipose tissue, abnormal hepatic glucose production and reduced glucose-stimulated insulin secretion.1 This panel of characteristics is caused at least in part by insensitivity of the insulin receptor and impairment of insulin signalling. In the early stages of developing T2DM, pancreatic insulin production increases to overcome resistance. However, during progression of T2DM, insulin secretion decreases owing to the depletion of pancreatic β-cells, resulting in absolute insulin deficiency and increase in plasma glucose levels.2 Long-term elevated plasma glucose levels are responsible for the development of microvascular complications, such as retino-, nephro- and neuropathy, and macrovascular complications, such as atherosclerosis, which are the most common long-term complications of T2DM.3,4 Correcting insulin resistance and substituting insulin currently is regarded as the gold standard of diabetes therapy. In addition, several medications are available (Table 1), which improve glucose utilization and uptake into insulin-sensitive tissues5 such as metformin6 and rosi- and pioglitazone.7 Release of insulin from pancreatic stores is achieved by sulphonylureas8 or incretin mimetics such as glucagon-like peptide 1 analogues and dipeptidyl peptidase 4 inhibitors.9 A major disadvantage of most of these interventions is that the daily dietary calorie intake usually stays too high and, thus, progression of T2DM is supported.10 In addition, only 50% of patients with T2DM reach glycaemic control with currently available therapy options.11,12 Many of the current T2DM treatments have doselimiting safety or tolerability issues, including hypoglycaemia 1

(sulphonylureas), oedema (glitazones), weight gain (sulphonylureas, glitazones) or gastrointestinal adverse events (glucagon-like peptide 1 analogues). Therefore, a medical need for therapies with lesser side effects, which in addition increase glycaemic control, becomes evident. These considerations led to the clinical development of a new class of antidiabetic drugs: inhibitors of the renal sodium-linked glucose transporter 2 (SGLT2).13 This approach aims at therapeutically induced glucose excretion with urine. It combines two medical needs: glycaemic control and reduction of already ingested calories (as glucose is secreted unmetabolized). For physicians, this is a new approach. Throughout the following, we review the molecular mechanism of action, regulatory status, efficacy and safety of SGLT2 inhibitors with focus on canagliflozin.

REGULATION OF GLUCOSE HOMEOSTASIS BY THE KIDNEYS The kidneys regulate the homeostasis of numerous substances of the body. In addition to the regulation of protein, mineral and acid–base balance, the kidneys have a crucial role in the control of energy homeostasis.14 Especially, the role of the kidneys in glucose metabolism is important and includes, in addition to gluconeogenesis and glucose utilization, glucose filtration and reabsorption.15 Owing to its low molecular weight, ingested glucose is filtered into primary urine and is recovered by the kidneys. Daily dietary glucose intake (~180 g) is filtered and recovered afterwards. This mechanism was important for survival in times of food scarcity. Glucose recovery is mediated by a tubular transport system that can reabsorb glucose in

Federal Institute for Drugs and Medical Devices, Bonn, Germany and 2Applied Pharmacy, University of Applied Sciences Kaiserslautern, Campus Pirmasens, Carl-Schurz-Str. 10–16, Pirmasens, Germany. Correspondence: Dr B Haas, Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3, Bonn 53175, Germany. E-mail: [email protected] 3 These authors contributed equally to this work. Received 16 June 2014; revised 16 September 2014; accepted 24 September 2014

SGLT2 inhibitors: focus on canagliflozin B Haas et al

2 combination with sodium (sodium-linked glucose transporter 1 and 2, SGLT1 and 2, respectively).16 This mechanism is not a unique feature of renal tubules, but also exists in other organs, such as the intestine. Whereas in the gastrointestinal tract especially SLC5A1 (SGLT1) is expressed, renal tubules express SLC5A1 and SLC5A2 (SGLT2).17 An overview of all known SGLT transporters and their tissue distribution is depicted in Table 2. Both transporters are able to reabsorb glucose. However, they show significant differences in affinities and transport capacity: SGLT2 has a greater transport capacity and reabsorbs glucose in combination with sodium in the ratio 1:1. SGLT1 has a higher affinity for glucose and reabsorbs glucose in combination with sodium in the ratio 1:2.17,18 These different transport properties Table 1.

are used by the kidneys to reabsorb all energy, leading to glucosefree urine. SGLT2 is localized mainly in the first two segments of the proximal tubular system (S1 and S2 segment). Owing to its high transport capacity, it is capable of reabsorbing about 90% of glucose from the primary urine. Ten percent of initially filtered glucose is recovered in the third section of the proximal tubule (S3 segment) by SGLT1 because of its high affinity. Both transporters are secondarily active owing to their dependence on the activity of the Na+/K+-ATPase in the basolateral membrane for the active removal of sodium. Glucose transporters (GLUT2 and GLUT1) facilitate glucose transport across the basolateral membrane in the early and more distal regions of the proximal tubule17 (Figure 1).

Overview of currently available antidiabetic medications

Class of antidiabetic Mode of action drug

Target organ/tissue Marketed drugsa

α-Glucosidase inhibitors

Intestine

Biguanides

Gliflozines (SGLT2 inhibitors) Glinides Gliptines (DPP4 inhibitors)

Competitive inhibition of α-glucosidase: reduction of enzymatic degradation of polysaccharids in the intestine and in consequence reduced glucose uptake AMPK activation and mGPD inhibition: inhibition of gluconeogenesis, increased glucose uptake and fattyacid oxidation; additional effects: reduction of glucose absorption from intestine, increase of insulin sensitivity, appetite suppressant SGLT2 inhibition: reduction of glucose reabsorption in kidney leads to increased glucose excretion via urine Sulphonylurea analogues with different pharmacokinetics: glucose-independent insulin release from pancreatic β-cells Inhibition of DPP4: delay of enzymatic incretine degradation

Acarbose, Miglitol

e.g., liver, muscle, Metformin kidney

Renal proximal tubule Pancreatic β-cells

Canagliflozin, Dapagliflozin, Empagliflozin Nateglinide, Repaglinide

e.g., kidney, Alogliptin, Linagliptin, Saxagliptin, Sitagliptin, intestine, lung, Vildagliptin vascular walls, plasma Incretine mimetics GLP1 receptor agonists: increased glucose sensitivity e.g., insulin target Albiglutide, Exenatide, Liraglutide, Lixisenatide (GLP1 analogues) of β-cells, increased insulin sensitivity in target tissues tissues, pancreas, due to removal of glucose toxicity, decreased CNS glucagon secretion from α-cells, delayed gastric emptying and increased feeling of satiety Sulphonylurea Glucose-independent insulin release from pancreatic Pancreatic β-cells 1st generation: Chlorpropamide, Tolbutamide β-cells 2nd generation: Glibenclamide, Gliclazide, Glipizide, Gliquidone 3rd generation: Glimepiride Thiazolidinediones PPARγ agonists: insulin-sensitizing effect on liver, Liver, muscle, Pioglitazone, Rosiglitazone (Glitazones) muscle and adipose tissue; increased adipocyte adipose tissue, differentiation CNS Abbreviations: AMPK, 5' adenosine monophosphate-activated protein kinase; CNS, central nervous system; DPP4, dipeptidyl peptidase 4; GLP1, glucagon-like peptide 1; mGPD, glycerophosphate dehydrogenase; PPARγ, peroxisome proliferator-activated receptor γ; SGLT2, sodium-linked glucose transporter 2. aMost prominent drugs marketed in the United States and/or Europe.

Table 2.

Substrates, substrate affinities and tissue distribution of SCL5 genes and the respective SGLT/SMIT transporter

Gene (transporter)

Substrate

Apparent affinity, K0.5 (mM)

SLC5A1 (hSGLT1)

D-Glucose

0.5 1 5 4100 0.050 450 19, 0.003 7.7, 0.15 Not known 0.27 36

D-Galactose

SLC5A2 (hSGLT2)

D-Glucose D-Galactose

SLC5A3 (cSMIT1) SLC5A4 (hSGLT3) SLC5A9 (hSGLT4) SLC5A10 (hSGLT5) SLC5A11 (rtSMIT2, rtSGLT6)

Myo-inositol D-Glucose D-Glucose, Miglitol D-Glucose, D-Mannose D-Glucose, D-Galactose Myo-inositol D-Glucose

Tissue expression Intestine, trachea, kidney, heart, brain, testis and prostate Kidney, brain, liver, thyroid, muscle and heart Brain, heart, kidney and lung Brain, intestine, kidney, lung, muscle, testis and uterus Intestine, kidney liver, brain, lung, trachea, uterus and pancreas Kidney Brain, kidney and intestine

Abbreviations: c, canine; h, human; rt, rat. Substrate specificity, apparent affinity (K0.5 for the substrates) and tissue distribution according to (16;17;40–47).

Nutrition & Diabetes (2014) 1 – 8

© 2014 Macmillan Publishers Limited

SGLT2 inhibitors: focus on canagliflozin B Haas et al

3

Figure 1. Schematic overview depicting the localization and function of SGLT1 and SGLT2 in the kidneys. SGLT2 reabsorbs glucose in combination with sodium in a 1:1 ratio in the tubular S1 segment, whereas SGLT1 reabsorbs glucose in combination with sodium in a 1:2 ratio in the tubular S3 segment. Both transporters are secondary active and driven by the activity of the Na+/K+-ATPase. Glucose reuptake into blood vessels is facilitated by glucose transporters GLUT1 and GLUT2.

There are certain mechanisms of compensation in cases of a surplus or failure of a transporter system. Diabetic patients, for example, have an increased glucose excretion in the primary urine. In this case, SLC5A2 expression is often increased, leading to an increase in the renal threshold for glucose in the final urine.19 As a consequence, the kidneys also retain body glucose under diabetic conditions. On the other hand, an inhibition of SGLT2 reduces glucose reabsorption in the S1 and S2 segments and can be compensated only in part by SGLT1 in the S3 segment so that complete reabsorption of glucose is not warranted.20 Under physiological circumstances, this dual mechanism of reabsorption allows the careful handling of an important energy source, namely glucose. On the basis of this knowledge, a new therapeutic principle for the treatment of T2DM was developed.13 Inhibition of the SGLT transport system results in increased urinary glucose excretion due to reduced glucose reabsorption. As a consequence plasma glucose levels are lowered, resulting in loss of calories and antihyperglycaemic effects beneficial for patients with T2DM. REGULATORY STATUS OF SGLT2 INHIBITORS Different SGLT2 inhibitors, also called gliflozins, are currently marketed or are undergoing clinical development and approval procedures (Table 3). In November 2012, the first-in-class SGLT2 © 2014 Macmillan Publishers Limited

inhibitor, dapagliflozin (Forxiga), was granted a marketing authorization by the European Medicines Agency (EMA). Dapagliflozin was initially rejected by the US Food and Drug Administration (FDA) owing to concerns noted by an Advisory Panel about potential increases in the risk of bladder and breast cancers associated with the drug.21 In January 2014, FDA granted marketing authorization for dapagliflozin (Farxiga) after new safety data on dapagliflozin from ongoing studies were provided. The FDA required to perform several post-marketing studies, in which 417 000 patients will be followed for 4–5 years to clarify whether dapagliflozin therapy is associated with increased risks for cardiovascular (CV) events, liver toxicity or cancer. Other postmarketing studies are required by the FDA to further assess bladder cancer risk and dapagliflozin’s effect in paediatric patients. Furthermore, an intense pharmacovigilance programme to monitor reports of liver toxicity and pregnancy outcomes has to be implemented by the company. Canagliflozin (Invokana) was approved by the FDA in March 2013, and in November 2013 by the EMA. Marketing authorizations followed a positive opinion of Advisory Committees, but concerns about safety of canagliflozin remained, which are addressed in several post-authorization safety studies (please also refer to the section on safety of SGLT2 inhibitors for details). In Europe, canagliflozin is labelled with an inverted black triangle in the package leaflet and the summary of product characteristics (SmPC),22 indicating that the drug is under Nutrition & Diabetes (2014) 1 – 8

SGLT2 inhibitors: focus on canagliflozin B Haas et al

4 Table 3.

Overview of the current regulatory status of SGLT inhibitors for the treatment of diabetes

SGLT inhibitor

Trial registration number Daily dose

Approval/developmental status

SGLT selectivity

Dapagliflozin Canagliflozin Empagliflozin Ipragliflozin Tofogliflozin Luseogliflozin Ertugliflozin LX4211 GSK189075 EGT0001442 BI 44847 EGT0001474 GSK-1614235 ISIS-SGLT2Rx

NA NA NA NA NA NA NCT01958671 NCT01742208 NCT00500331 NCT01377844 NCT00558909 NCT00924053 NCT01607385 NCT00836225

Approved by EMA (2012/11), FDA (2014/01), PMDA (2014/03) Approved by FDA (2013/03), EMA (2013/11) Approved by EMA (2014/05), FDA (2014/08) Approved by PMDA (2014/01) Approved by PMDA (2014/3) Approved by PMDA (2014/03) Phase III recruiting Phase II Phase II Phase II Phase I Phase I Phase I Phase I

SGLT2 SGLT2 SGLT2 SGLT2 SGLT2 SGLT2 SGLT2 SGLT1/SGLT2 SGLT2 SGLT2 SGLT2 SGLT2 SGLT1 SGLT2

5, 10 mg 100, 300 mg 10, 25 mg 25, 50 mg 20 mg 2.5, 5 mg 5, 10 mg Not yet determined Not yet determined Not yet determined Not yet determined Not yet determined Not yet determined Not yet determined

Abbreviations: EMA, European Medicines Agency; FDA, Food and Drug Administration; NA, not applicable; PMDA, Pharmaceuticals and Medical Devices Agency. Japan; source of information: homepages of the FDA,48 EMA,22 PMDA,49 (www.clinicaltrials.gov).

additional monitoring by regulatory authorities. On March 2014, the EMA recommended granting of a marketing authorization for a third SGLT2 inhibitor empaglifozin (Jardiance), and in May 2014 the European Commission followed the positive vote of the EMA. Initially, FDA rejected approval of empagliflozin in March 2014 owing to previously observed deficiencies at a facility where empagliflozin is manufactured, but finally approved it in August 2014. In Japan four SGLT2 inihibitors, namely dapagliflozin, ipragliflozin, tofogliflozin and luseogliflozin, were approved in 2014 (Table 3). PHARMACOKINETICS OF CANAGLIFLOZIN For gliflozins, comprehensive data from phase II and III clinical trials are available.23 Throughout the following sections, we focus exemplarily on canagliflozin as the first SGLT2 inhibitor licensed in the US and Europe. Canagliflozin has an oral bioavailability of 65% with a maximum effect after 30–120 min. Its pharmacokinetic profile is independent of age, body weight, gender, ethnicity, administration with food and mild-to-moderate hepatic impairment. Importantly, the amount of glucose filtered in the glomerulus depends not only on plasma glucose levels but also on the glomerular filtration rate (GFR). Therefore, it can be expected that with decreasing renal function a decrease of activity is paralleled. Unlike with other antidiabetic drugs, such as metformin or glimepiride, with impaired renal function there is no risk to the patient, but the treatment becomes gradually ineffective. As a consequence, canagliflozin therapy should not be initiated in patients with end-stage renal disease, on dialysis, or with renal impairment at an eGFR o 60 ml–1 min–1 per 1.73 m2. Clinical trials24 confirmed that significant glycaemic efficacy still was observed in subjects with eGFR values of ⩾ 30 to o50 ml–1 min–1 per 1.73 m2, even though the reductions in glycosylated haemoglobin A1c (HbA1c) and fasting plasma glucose were smaller than seen in subjects with higher baseline eGFR values (see section below). In canagliflozin-treated patients whose eGFR falls below 60 ml–1 min–1 per 1.73 m2, canagliflozin dose should be adjusted to or maintained at the low dose of 100 mg once daily. Approximately 40% of administered canagliflozin is excreted unmetabolized in faeces; minor metabolism of canagliflozin occurs via uridine 5'-diphospho-glucuronosyltransferase, resulting in two pharmacologically inactive metabolites (canagliflozin O-glucuronides) mainly excreted via urine. With a half-life of 11–13 h a once-daily regimen is therapeutically sufficient (SmPC Invokana22). Nutrition & Diabetes (2014) 1 – 8

PHARMACOLOGY OF CANAGLIFLOZIN—EFFECTS ON GLUCOSE METABOLISM, BODY WEIGHT AND THE CV SYSTEM Canagliflozin is a competitive, reversible, highly selective SGLT2 inhibitor with a 250-fold selectivity towards SGLT2 over SGLT1. Inhibition of SGLT2 by canagliflozin leads to a reduction of glucose reabsorption from primary urine. The induced glucosuria of ~ 70 g per day results in a loss of glucose and optimized plasma glucose control.20,25 Canagliflozin is indicated in patients with T2DM to improve glycaemic control as monotherapy when diet and exercise alone do not provide adequate glycaemic control and in patients for whom the use of metformin is considered inappropriate owing to intolerance or contraindications. Furthermore, it is indicated as add-on therapy with other antihyperglycaemic medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (SmPC Invokana22). Table 4 summarizes the efficacy data of canagliflozin derived from phase III clinical trials. Canagliflozin is used at doses of 100 or 300 mg and the primary end point in the pivotal studies was lowering HbA1c. Serving as secondary end points, effects on fasting plasma glucose, body weight, blood pressure and lipid parameters were investigated. As reflected in the European Public Assessment Report (EPAR) of canagliflozin,26 7803 subjects were randomized. This included 4994 subjects treated with canagliflozin (100 or 300 mg), 1583 treated with placebo and 1226 treated with an active comparator (744 sitagliptin, 482 glimepiride). Taken together, depending on the premedication and baseline HbA1c placebo-adjusted reduction, between − 0.57% and − 0.91% (100 mg dose) and − 0.70% and − 1.16% (300 mg dose) was observed, respectively. In poorly controlled diabetic patients even a reduction of up to – 2.42% was achieved. The favourable effect on HbA1c values was consistent with an improvement of secondary end points such as fasting plasma glucose. The efficacy of canagliflozin was reduced in patients with moderate renal impairment. A meta-analysis of all subjects from placebo-controlled phase III studies with eGFR ⩾ 30 to o60 ml–1 min–1 per 1.73 m2 (1085 subjects) showed a decrease in HbA1c from baseline by − 0.47% and − 0.38% for canagliflozin 300 and 100 mg, respectively, compared with placebo.26 This is in line with the mode of action (see sections above) and is reflected in the SmPC22 as a warning for patients with end-stage renal disease, on dialysis, or with renal impairment and an eGFR o60 ml–1 min–1 per 1.73 m2. The improvement in glycaemic control in T2DM patients achieved by SGLT2 inhibition also led to the consideration to use SGLT2 inhibitors in conjunction with insulin therapy in type 1 diabetes mellitus. So far, only limited data from studies with type 1 diabetic patients are available. Studies with empagliflozin in © 2014 Macmillan Publishers Limited

© 2014 Macmillan Publishers Limited PC, AC, PG 52 wks (26 wks/26 wks)

Add-on to AHA monotherapya NCT01106677b,52 add-on to metformin monotherapy (169 centres)

PC, PG 52 (26 wks/26 wks)

Add-on to dual-combination AHA therapya NCT01106625, add-on to metformin+sulphonylurea (85 centres)

PC, PG104 wks (26 wks/78 wks)

Special population studiesa NCT01106651,29 older adults (⩾55 to ⩽ 80 years of age) (90 centres)

PC, PG 18 wks (18 wks/no extension)

Sulphonylurea substudy (80 centres)

100 mg 300 mg 100 mg 300 mg 100 mg 300 mg

Canagliflozin Canagliflozin Placebo Canagliflozin Canagliflozin Placebo Canagliflozin Canagliflozin

Placebo

Canagliflozin Canagliflozin Placebo Canagliflozin Canagliflozin

100 mg 300 mg

100 mg 300 mg

100 mg 300 mg

100 mg 300 mg

100 mg 300 mg

Placebo Canagliflozin 100 mg Canagliflozin 300 mg Placebo

Placebo Canagliflozin 100 mg Canagliflozin 300 mg Placebo Canagliflozin 100 mg Canagliflozin 300 mg Placebo Canagliflozin 100 mg Canagliflozin 300 mg Canagliflozin 300 mg Sitagliptin 100 mg

Placebo Canagliflozin 100 mg Canagliflozin 300 mg Sitagliptin 100 mg Canagliflozin 100 mg Canagliflozin 300 mg Sitagliptin 100 mg Canagliflozin 100 mg Canagliflozin 300 mg Glimepiride (titrated from 1–6 or 8 mg)

Placebo Canagliflozin Canagliflozin Canagliflozin Canagliflozin Canagliflozin Canagliflozin

Intervention

1445 1441c 565 566 587 45 42 40

c

1441c

90 89 87 89 89

237 241 236 90

156 157 156 150 155 152 115 113 114 377 378

183 368 367 366 365 360 354 483 485 482

192 195 197 191 194 47 44

No. subjects per treatment arm (ITT)

Δ BL to wk 18 in HbA1c

Δ BL to wk 18 in HbA1c

Assessment of hazard ratio for MACE events

Δ BL to wk 52 in HbA1c

Δ BL to wk 26 in HbA1c

Δ BL to wk 26 in HbA1c

Δ BL to wk 52 in HbA1c

Δ BL to wk 26 in HbA1c

Δ BL to wk 52 in HbA1c

Δ BL to wk 26 in HbA1c

Δ BL to wk 52 in HbA1c

Δ BL to wk 52 in HbA1c

Δ BL to wk 26 in HbA1c

Δ BL to wk 26 in HbA1c

Δ BL to wk 52 in HbA1c

Δ BL to wk 26 in HbA1c

Primary end point

0.01 ± 0.032 − 0.63 ± 0.031 − 0.72 ± 0.030 0.04 ± 0.146 − 0.70 ± 0.145 − 0.79 ± 0.147

− 0.33 ± 0.090 − 0.44± 0.089 − 0.07 ± 0.104 − 0.19 ± 0.104 − 0.33 ± 0.103

7.89 ± 0.898 7.97± 0.805 8.02 ± 0.917 7.88 ± 0.886 7.97 ± 0.805

8.20 ± 0.837 8.33 ± 0.905 8.27 ± 0.894 8.49 ± 1.130 8.29 ± 0.831 8.28 ± 1.005

− 0.03 ± 0.063 − 0.60 ± 0.063 − 0.73 ± 0.064 − 0.03 ± 0.090

− 0.13 ± 0.075 − 0.85 ± 0.075 − 1.06 ± 0.076 − 0.01 ± 0.077 − 0.74 ± 0.077 − 0.97 ± 0.078 − 0.26 ± 0.069 − 0.89 ± 0.069 − 1.03 ± 0.070 − 1.03 ± 0.048 − 0.66 ± 0.049

− 0.17 ± 0.060 − 0.79 ± 0.044 − 0.94 ± 0.044 − 0.82 ± 0.044 − 0.73 ± 0.047 − 0.88 ± 0.047 − 0.73 ± 0.047 − 0.82 ± 0.039 − 0.93 ± 0.039 − 0.81 ± 0.039

0.14 ± 0.065 − 0.77 ± 0.065 − 1.03 ± 0.064 − 0.75 ± 0.067 − 1.04 ± 0.067 − 2.13 ± 0.220 − 2.56 ± 0.227

Change in HbA1c from baseline (%), LS mean (SE)

7.76 ± 0.785 7.77 ± 0.773 7.69 ± 0.779 8.02 ± 0.917

8.12 ± 0.896 8.13 ± 0.926 8.13 ± 0.942 8.12 ± 0.896 8.13 ± 0.926 8.13 ± 0.942 8.00 ± 1.010 7.99 ± 0.940 7.84 ± 0.911 8.12 ± 0.910 8.13 ± 0.916

7.96 ± 0.896 7.94 ± 0.879 7.95 ± 0.931 7.92 ± 0.875 7.94 ± 0.879 7.95 ± 0.931 7.92 ± 0.875 7.78 ± 0.787 7.79 ± 0.779 7.83 ± 0.795

7.97 ± 0.955 8.06 ± 0.959 8.01 ± 0.988 8.06 ± 0.959 8.01 ± 0.988 10.59 ± 0.873 10.62 ± 0.955

Baseline HbA1c (%), mean ± s.d.

Abbreviations: Δ, change from; AC, active-controlled; AHA, anti-hyperglycaemic agent; BL, baseline; eGFR, estimated glomerular filtration rate; ITT, intent-to-treat population; LS, least-squares; MACE, major adverse cardiovascular events; No., number; PC, placebo-controlled; PG, parallel group; QD, once daily; SU, sulphonylurea; wk(s), week(s). Source of information: European Public Assessment Report (EPAR) of canagliflozin26 if not otherwise indicated. aDouble-blind and randomized. bSubjects assigned to placebo were switched to sitagliptin during the double-blind extension period. cRandomized and treated subjects (that is, safety analysis set).

PC, PG 18 wks (18 wks/no extension)

PC, PG duration is event driven based on number of MACE events

Insulin substudy (316 centres)

Cardiovascular assessment study with efficacy substudiesa NCT01032629, cardiovascular study (369 centres)

52-wks extension Period

PC, PG 52 wks (26 wks/26 wks)

AC, PG 52 wks (52 wks/no extension)

NCT01137812,53 add-on to metformin+sulphonylurea (140 centres)

NCT01064414,24 moderate renal impairment (eGFR ⩾ 30 to o50 ml–1 min–1 per 1.73 m2) (89 centres)

PC, PG 52 wks (26 wks/26 wks)

NCT01106690,b add-on to metformin+pioglitazone (74 centres)

52-wks extension period

AC, PG 104 wks (52 wks/52 wks)

NCT00968812,30 add-on to metformin monotherapy (157 centres)

52-wks extension period

PG 26 wks (26 wks/no extension)

52 wks extension period

PC, PG 52 wks (26 wks/26 wks)

High glycaemic substudy monotherapy (40 centres)

Monotherapya NCT01081834,50,51 main studyb monotherapy (90 centres)

Design, duration (duration to primary end point/duration of extension phase)

Efficacy data of canagliflozin in phase III clinical trials

Trial registration number/study type

Table 4.

SGLT2 inhibitors: focus on canagliflozin B Haas et al

5

Nutrition & Diabetes (2014) 1 – 8

SGLT2 inhibitors: focus on canagliflozin B Haas et al

6

streptozotocin-induced diabetic rats27 and results from a Phase II trial indicate beneficial effects of SGLT2 inhibition on reducing HbA1c, body weight, total daily insulin dose and hypoglycaemic events.28 Further studies with empagliflozin and other SGLT2 inhibitors are currently underway to prove their efficacy and safety in type 1 diabetes mellitus patients. Canagliflozin therapy not only was effective in improving glucose metabolism. The induced glucosuria of 70 g per day additionally leads to an energy deficit of 300 kcal per day, which translates into a body weight reduction of − 1.84 and − 2.43 kg (100 and 300 mg canagliflozin, respectively).26 Interestingly, weight loss stabilizes after a couple of weeks, even so glucosuria persists and calorie loss is maintained. Compensatory mechanisms such as increased food intake might explain these findings. That weight loss was indeed caused by loss of fat mass and not osmotic diuresis could be shown by dual-energy X-ray absorptiometry body composition analysis in clinical trials,29,30 a diagnostic technique that can distinguish between fat, bone mineral and other fat-free mass that does not include bone. The weightreducing characteristics of SGLT2 inhibitors in T2DM patients also might be effective in non-diabetic overweight subjects. This not only creates the option to widen the indication for the use of SGLT2 inhibitors as antiobesity drugs, but also poses the risk for drug abuse, for instance, as a weight-reducing agent or doping compound. Under canagliflozin therapy, a clinically relevant lowering of systolic (−3.9 and − 5.3 mmHg for the 100 and 300 mg dose, respectively) and diastolic (−2.1 and − 2.5 mm Hg for the 100 and 300 mg dose, respectively) blood pressure was observed in placebo-controlled studies, which is a desirable additional effect of canagliflozin and not usually expected for a glucose-lowering drug. This was not accompanied by an increased compensatory heart rate. Blood pressure reduction correlates with a mild diuretic effect and haemoconcentration (reflected by increased haemoglobin and haematocrit) observed during canagliflozin treatment.22,31 Whether the renin–angiotensin–aldosterone system is counter-regulatory activated upon canagliflozin treatment as observed in patients with genetic loss of SLC5A2 (familial renal glucosuria)32 is currently under investigation. T2DM usually entails marked long-term clinical consequences such as blindness and neuropathies derived from micro- or macroangiopathy. The question whether these hazardous clinical consequences can be reduced by canagliflozin therapy is currently under investigation and can, thus, not be answered conclusively at present. SAFETY OF CANAGLIFLOZIN Among the most important safety aspects of antidiabetic drugs is their low propensity to induce hypoglycaemia. Interestingly, during clinical development of SGLT2 inhibitors hardly any hypoglycaemia was observed due to the following reasons: first, glucose excretion decreases along with decreasing plasma glucose levels and; second, counter-regulatory mechanisms are not affected by SGLT2 inhibition as gliflozins act independently from insulin. This low risk for hypoglycaemia can be regarded an advantage of this class of medicines as compared with classical antidiabetic compounds such as insulin or sulphonylureas. The adverse events observed with canagliflozin reflect its pharmacodynamic action. Almost no organ toxicities were found during pre-clinical development;26 only in long-term rat studies toxicities in terms of excessive bone growth (hyperostosis) and renal tubular tumours were observed, probably caused by undesired SGLT1 inhibition in the gastrointestinal tract and subsequent carbohydrate malabsorption. However, this is regarded as a species-specific phenomenon, as in rats canagliflozin is poorly absorbed from the gut and hence high local concentrations are reached, which are able to inhibit SGLT1 Nutrition & Diabetes (2014) 1 – 8

located at the surface of the intestinal mucosa. Carbohydrate malabsorption is accompanied by increased calcium absorption from the gut, probably causing hyperostosis and renal tubular tumours in the rat. Nevertheless, SGLT2 inhibition can lead to unexpected sequels. It appears logical that glucosuria, deliberately induced by SGLT2 inhibition, favours urinary tract infections, as glucose serves as nutrient for bacteria. Some increase in urinary tract infections was indeed observed in regulatory safety trials; however, serious cases were rare.33 Much more pronounced were canagliflozin-related increases in female mycotic genital infections. Infections are not serious in nature and easy to treat, but patients and prescribers should be aware of it. Another reported side effect of canagliflozin treatment is osmotic diuresis and subsequent water loss. However, unlike that observed during classical osmotic diuresis, where sodium is retained, SGLT2 inhibition causes sodium loss. This can be attributed to the fact that sodium is co-transported with glucose by SGLT2 (Figure 1). In fact, canagliflozin leads to a decrease in blood pressure and haemoconcentration, reflected by increased haemoglobin and haematocrit (increased levels of plasma lipoproteins could also be a consequence of it, see below), but notably no hypernatraemia as a trigger for thirst. The latter may explain why, in particular, elderly patients do not develop sufficient thirst to compensate for water loss and consequently tend to have dehydration, unstable blood pressure or syncope.34,35 A rather sharp decrease in blood pressure can particularly occur at the beginning of therapy; later on, counterregulatory mechanisms like reduction in glomerular perfusion minimize diuresis and blood pressure reduction. In order to avoid haemodynamic problems in vulnerable patients, canagliflozin therapy should be initiated with the lower dose of 100 mg per day (instead of 300 mg per day). Consequently, concomitant use of canagliflozin and loop diuretics is not recommended.22 Regarding kidney function, there was intensive discussion during the licensing procedures whether canagliflozin might damage kidneys, especially when kidney function is already impaired by diabetic nephropathy.26 The above-mentioned haemoconcentration observed under canagliflozin therapy also leads to an increase in serum creatinine, which is usually a marker for renal damage. However, it could be shown that its increase with canagliflozin treatment is fully reversible after cessation, so that renal damage can be excluded. Contrarily, canagliflozin may help protect kidneys because it appears to reduce GFR by reducing intra-glomerular pressure and hence might retard glomerular sclerosis. This possibility is currently under investigation.36 There was also a discussion on the cancer risk of SGLT2 inhibitors. In phase III studies with the first SGLT2 inhibitor that was applied for marketing authorization, dapagliflozin, a marked numerical imbalance in the cases of bladder cancer was observed between the dapagliflozin and comparator groups; however, the number of cases was low. From 5501 patients under dapagliflozin 9 (0.16%) suffered from bladder cancer, whereas in the placebo group 1 of 3184 patients was affected (0.03%).21,37 Reassuringly, no increase in bladder cancer was found subsequently with the other SGLT2 inhibitors, so that a chance finding is most likely.38 Carcinogenicity studies in animals were conducted with all SGLT2 inhibitors under development. For dapagliflozin, no tumours were observed in these studies.37 Canagliflozin caused certain types of tumours (for example, renal tubular tumours) in rats, but mechanistic studies revealed that off-target inhibition of SGLT1 in these animals was the underlying mechanism.26 For canagliflozin, a long-term CV safety study is ongoing (CANVAS), which was originally planned to demonstrate CV safety in patients with increased risk for CV events (Table 4).39 According to the present knowledge from a meta-analysis of clinical trials including an interim analysis of the CANVAS study provided in the EPAR of canagliflozin,26 canagliflozin does not increase the overall © 2014 Macmillan Publishers Limited

SGLT2 inhibitors: focus on canagliflozin B Haas et al

7 CV risk. Notably, in patients without CV disease, canagliflozintreated patients performed numerically better than the comparator therapies in respect to major CV events; the point estimate for the hazard ratio was 0.52, albeit with a broad 95% confidence interval, including 1.26 This positive effect (if confirmed) could be related to the blood pressure-lowering effect of canagliflozin. On the other hand, in patients with existing CV disease the decrease in blood pressure, which is most pronounced immediately after onset of therapy, could be hazardous and could hence abolish the positive effect. For instance, the incidence of non-fatal stroke was numerically increased in the canagliflozin groups; further data from the CANVAS trial will show whether this effect is true. Also relevant for assessing CV safety is the plasma lipid profile; it turned out that canagliflozin (and also other SGLT2 inhibitors) slightly increased the levels of both high-density lipoprotein and low-density lipoprotein cholesterol.33 This simultaneous increase of both lipoproteins might be a consequence of the observed haemoconcentration (see above) and probably does not imply increased CV risk. Further information on CV risk and also on other safety issues, for example, long-term renal safety, safety in special populations, and— as far as possible—tumour incidence, is expected from ongoing trials. CONCLUSION SGLT2 inhibitors are a promising new class of antidiabetic drugs currently approved in Europe, the US and Japan. They allow weight-reducing and effective glycaemic control combined with a low risk of hypoglycaemia. The medication can be used in any stage of the disease independently of existing co-medications. Furthermore, the use of SGLT2 inhibitors in addition to insulin therapy in type 1 diabetic patients is conceivable, for example, to improve their glycaemic profile and avoid hyperglycaemia. However, whether SGLT2 inhibitor therapy also improves the clinical consequences of diabetes, such as micro- or macrovascular late complications, cannot be answered at present owing to immature clinical data, and provides some uncertainty of this class of drugs. Caution with these drugs should be exercised in elderly patients (tendency to dehydration and urinary-, genital infections), patients with recurrent urinary tract or genital infections and patients with reduced renal function (reduced efficacy). CONFLICT OF INTEREST The authors declare no conflict of interest.

ACKNOWLEDGEMENTS This review article was supported by intramural funding of the Federal Institute for Drugs and Medical Devices.

DISCLAIMER The opinions mentioned throughout the following article are personal views of the authors and do not reflect an official position of the Federal Institute for Drugs and Medical Devices.

AUTHOR CONTRIBUTIONS BH, NE and PM wrote the manuscript. BH, MDSH and VP prepared figures and tables. All authors read and approved the final manuscript.

REFERENCES 1 Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 2005; 365: 1333–1346. 2 Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003; 46: 3–19.

© 2014 Macmillan Publishers Limited

3 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589. 4 Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, Duckworth WC et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288–2298. 5 Liday C. Overview of the guidelines and evidence for the pharmacologic management of type 2 diabetes mellitus. Pharmacotherapy 2011; 31(12 Suppl): 37S–43S. 6 Ferrannini E. The target of metformin in type 2 diabetes. N N Engl J Med 2014; 371: 1547–1548. 7 Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004; 351: 1106–1118. 8 Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 737–754. 9 Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298: 194–206. 10 Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197–1209. 11 Mitka M. More patients get good diabetes control, but only a minority meet all goals. JAMA 2013; 309: 1335–1336. 12 Lawrence DB, Ragucci KR, Long LB, Parris BS, Helfer LA. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006; 12: 466–471. 13 Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov 2010; 9: 551–559. 14 Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl 2011; 120: S1–S6. 15 Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 2010; 27: 136–142. 16 Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007; 261: 32–43. 17 Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011; 91: 733–794. 18 Barfuss DW, Schafer JA. Differences in active and passive glucose transport along the proximal nephron. Am J Physiol 1981; 241: F322–F332. 19 Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951; 30: 125–129. 20 Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA. SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus. J Clin Pharmacol 2012; 52: 457–463. 21 Burki TK. FDA rejects novel diabetes drug over safety fears. Lancet 2012; 379: 507. 22 European Medicins Agency [http://www.ema.europa.eu/ema/]. 2014. 23 Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013; 159: 262–274. 24 Yale JF, Bakris G, Cariou B, Nieto J, Wajs E, Figueroa K et al. Efficacy and Safety of Canagliflozin (CANA) in Subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) Over 52 Weeks. Can J Diabetes 2013; 37(Suppl 4): S27. 25 Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 2012; 44: 375–393. 26 Committee for Medicinal Products for Human Use. European Public Assessment Report (EPAR) Canagliflozin. European Medicines Agency 2013. EMA/374133/2013. 27 Luippold G, Klein T, Mark M, Grempler R. Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus. Diabetes Obes Metab 2012; 14: 601–607. 28 Lamos EM, Younk LM, Davis SN. Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Invest Drugs 2014; 23: 875–882. 29 Bode B, Stenlof K, Sullivan D, Fung A, Usiskin K. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract (1995 ) 2013; 41: 72–84. 30 Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013; 382: 941–950. 31 Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 2014; 8: 262–275. 32 Calado J, Sznajer Y, Metzger D, Rita A, Hogan MC, Kattamis A et al. Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion. Nephrol Dial Transplant 2008; 23: 3874–3879.

Nutrition & Diabetes (2014) 1 – 8

SGLT2 inhibitors: focus on canagliflozin B Haas et al

8 33 Nicolle LE, Capuano G, Fung A, Usiskin K. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014; 126: 7–17. 34 Elmore LK, Baggett S, Kyle JA, Skelley JW. A review of the efficacy and safety of canagliflozin in elderly patients with type 2 diabetes. Consult Pharm 2014; 29: 335–346. 35 Sinclair A, Bode B, Harris S, Vijapurkar U, Mayer C, Fung A et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord 2014; 14: 37. 36 De NL, Gabbai FB, Liberti ME, Sagliocca A, Conte G, Minutolo R. Sodium/Glucose Cotransporter 2 Inhibitors and Prevention of Diabetic Nephropathy: Targeting the Renal Tubule in Diabetes. Am J Kidney Dis 2014; 64: 16–24. 37 Committee for Medicinal Products for Human Use. European Public Assessment Report (EPAR) Dapagliflozin. European Medicines Agency 2012. EMA/689976/2012. 38 Reilly TP, Graziano MJ, Janovitz EB, Dorr TE, Fairchild C, Lee F et al. Carcinogenicity risk assessment upports the chronic Ssfety of dapagliflozin, an inhibitor of sodium-slucose co-transporter 2, in the reatment of type 2 diabetes mellitus. Diabetes Ther 2014; 5: 73–96. 39 Neal B, Perkovic V, de ZD, Mahaffey KW, Fulcher G, Stein P et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J 2013; 166: 217–223. 40 Tazawa S, Yamato T, Fujikura H, Hiratochi M, Itoh F, Tomae M et al. SLC5A9/SGLT4, a new Na+ − dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 2005; 76: 1039–1050. 41 Diez-Sampedro A, Wright EM, Hirayama BA. Residue 457 controls sugar binding and transport in the Na(+)/glucose cotransporter. J Biol Chem 2001; 276: 49188–49194. 42 Kothinti RK, Blodgett AB, North PE, Roman RJ, Tabatabai NM. A novel SGLT is expressed in the human kidney. Eur J Pharmacol 2012; 690: 77–83. 43 Aouameur R, Da CS, Bissonnette P, Coady MJ, Lapointe JY. SMIT2 mediates all myo-inositol uptake in apical membranes of rat small intestine. Am J Physiol Gastrointest Liver Physiol 2007; 293: G1300–G1307. 44 Diez-Sampedro A, Lostao MP, Wright EM, Hirayama BA. Glycoside binding and translocation in Na(+) − dependent glucose cotransporters: comparison of SGLT1 and SGLT3. J Membr Biol 2000; 176: 111–117.

Nutrition & Diabetes (2014) 1 – 8

45 Hummel CS, Lu C, Loo DD, Hirayama BA, Voss AA, Wright EM. Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol 2011; 300: C14–C21. 46 Hager K, Hazama A, Kwon HM, Loo DD, Handler JS, Wright EM. Kinetics and specificity of the renal Na+/myo-inositol cotransporter expressed in Xenopus oocytes. J Membr Biol 1995; 143: 103–113. 47 Voss AA, Diez-Sampedro A, Hirayama BA, Loo DD, Wright EM. Imino sugars are potent agonists of the human glucose sensor SGLT3. Mol Pharmacol 2007; 71: 628–634. 48 US Food and Drug Administaration [http://www.fda.gov/]. 2014. 49 Pharmaceuticals and Medical Devices Agency, Japan [http://www.pmda.go.jp/]. 2014. 50 Stenlof K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013; 15: 372–382. 51 Stenlof K, Cefalu WT, Kim KA, Jodar E, Alba M, Edwards R et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014; 30: 163–175. 52 Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56: 2582–2592. 53 Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 2013; 36: 2508–2515.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/ by/4.0/

© 2014 Macmillan Publishers Limited